AAAAAA
Results: 1-25/31
Authors:
Baxter, GF
Citation: Gf. Baxter, Increased risk for ischaemic events is related to combined RAS polymorphism - Commentary, HEART, 85(4), 2001, pp. 462-462
Authors:
Yamashita, N
Baxter, GF
Yellon, DM
Citation: N. Yamashita et al., Exercise directly enhances myocardial tolerance to ischaemia-reperfusion injury in the rat through a protein kinase C mediated mechanism, HEART, 85(3), 2001, pp. 331-336
Authors:
Baxter, GF
Citation: Gf. Baxter, Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in type 2 diabetic patients - Commentary, HEART, 85(1), 2001, pp. 91-91
Authors:
Jaberansari, MT
Baxter, GF
Muller, CA
Latouf, SE
Roth, E
Opie, LH
Yellon, DM
Citation: Mt. Jaberansari et al., Angiotensin-converting enzyme inhibition enhances a subthreshold stimulus to elicit delayed preconditioning in pig myocardium, J AM COL C, 37(7), 2001, pp. 1996-2001
Authors:
Ebrahim, Z
Yellon, DM
Baxter, GF
Citation: Z. Ebrahim et al., Bradykinin elicits "second window" myocardial protection in rat heart through an NO-dependent mechanism, AM J P-HEAR, 281(3), 2001, pp. H1458-H1464
Authors:
Baxter, GF
Ferdinandy, P
Citation: Gf. Baxter et P. Ferdinandy, Delayed preconditioning of myocardium: current perspectives, BAS R CARD, 96(4), 2001, pp. 329-344
Authors:
Baxter, GF
Mocanu, MM
Brar, BK
Latchman, DS
Yellon, DM
Citation: Gf. Baxter et al., Cardioprotective effects of transforming growth factor-beta 1 during earlyreoxygenation or reperfusion are mediated by p42/p44 MAPK, J CARDIO PH, 38(6), 2001, pp. 930-939
Authors:
Dana, A
Baxter, GF
Yellon, DM
Citation: A. Dana et al., Delayed or second window preconditioning induced by adenosine al receptor activation is independent of early generation of nitric oxide or late induction of inducible nitric oxide synthase, J CARDIO PH, 38(2), 2001, pp. 278-287
Authors:
Mocanu, MM
Maddock, HL
Baxter, GF
Lawrence, CL
Standen, NB
Yellon, DM
Citation: Mm. Mocanu et al., Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide, CIRCULATION, 103(25), 2001, pp. 3111-3116
Authors:
Baxter, GF
Citation: Gf. Baxter, Haemochromatosis gene mutations in idiopathic dilated cardiomyopathy - Commentary, HEART, 84(5), 2000, pp. 547-547
Authors:
Baxter, GF
Citation: Gf. Baxter, Polymorphisms of the P-selectin gene and risk of myocardial infarction in men and women in the ECTIM extension study - Commentary, HEART, 84(5), 2000, pp. 551-552
Authors:
Baxter, GF
Citation: Gf. Baxter, Plasma N terminal pro-brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina - Commentary, HEART, 84(4), 2000, pp. 424-424
Authors:
Baxter, GF
Citation: Gf. Baxter, Increased formation of F-2-isoprostanes in patients with severe heart failure - Commentary, HEART, 84(4), 2000, pp. 440-440
Authors:
Baxter, GF
Citation: Gf. Baxter, Increased plasma lipoprotein (a) concentrations in Behcet's disease and its relation to vascular events - Commentary, HEART, 84(2), 2000, pp. 209-209
Authors:
Baxter, GF
Citation: Gf. Baxter, Troglitazone decreases collagen accumulation in prediabetic stage of a type II diabetic rat model - Commentary, HEART, 84(2), 2000, pp. 210-210
Authors:
Baxter, GF
Citation: Gf. Baxter, Decreased adrenomedullin production in the coronary circulation of patients with coronary artery disease - Commentary, HEART, 84(1), 2000, pp. 88-88
Authors:
Yellon, DM
Baxter, GF
Citation: Dm. Yellon et Gf. Baxter, Protecting the ischaemic and reperfused myocardium in acute myocardial infarction: distant dream or near reality?, HEART, 83(4), 2000, pp. 381-387
Authors:
Baxter, GF
Citation: Gf. Baxter, Production of hepatocyte growth factor during acute myocardial infarction - Commentary, HEART, 83(4), 2000, pp. 455-455
Authors:
Baxter, GF
Hale, SL
Miki, T
Kloner, RA
Cohen, MV
Downey, JM
Yellon, DM
Citation: Gf. Baxter et al., Adenosine A(1) agonist at reperfusion trial (AART): Results of a three-center, blinded, randomized, controlled experimental infarct study, CARDIO DRUG, 14(6), 2000, pp. 607-614
Authors:
Mocanu, MM
Baxter, GF
Yue, Y
Critz, SD
Yellon, DM
Citation: Mm. Mocanu et al., The p38 MAPK inhibitor, SB203580, abrogates ischaemic preconditioning in rat heart but timing of administration is critical, BAS R CARD, 95(6), 2000, pp. 472-478
Authors:
Aitchison, KA
Baxter, GF
Awan, MM
Smith, RM
Yellon, DM
Opie, LH
Citation: Ka. Aitchison et al., Opposing effects on infarction of delta and kappa opioid receptor activation in the isolated rat heart: implications for ischemic preconditioning, BAS R CARD, 95(1), 2000, pp. 1-10
Authors:
Yellon, DM
Baxter, GF
Citation: Dm. Yellon et Gf. Baxter, Sodium-hydrogen exchange in myocardial reperfusion injury, LANCET, 356(9229), 2000, pp. 522-523
Authors:
Mocanu, MM
Baxter, GF
Yellon, DM
Citation: Mm. Mocanu et al., Caspase inhibition and limitation of myocardial infarct size: protection against lethal reperfusion injury, BR J PHARM, 130(2), 2000, pp. 197-200
Authors:
Yellon, DM
Baxter, GF
Citation: Dm. Yellon et Gf. Baxter, Reperfusion injury revisited - Is there a role for growth factor signalingin limiting lethal reperfusion injury?, TREND CARD, 9(8), 1999, pp. 245-249
Authors:
Mocanu, MM
Gadgil, S
Yellon, DM
Baxter, GF
Citation: Mm. Mocanu et al., Mibefradil, a T-type and L-type calcium channel blocker, limits infarct size through a glibenclamide-sensitive mechanism, CARDIO DRUG, 13(2), 1999, pp. 115-122